Open Access

[Retracted] miRNA‑520c‑3p accelerates progression of nasopharyngeal carcinoma via targeting RAB22A

  • Authors:
    • Xiaohan Sun
    • Wenrui Xu
    • Chuanshan Zang
    • Na Li
  • View Affiliations

  • Published online on: October 1, 2020     https://doi.org/10.3892/ol.2020.12182
  • Article Number: 319
  • Copyright : © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Oncol Lett 19: [Related article:] 771-776, 2020; DOI: 10.3892/ol.2019.11144

Following the publication of this article, the authors have contacted the Editor to request its retraction on account of having been unable to reproduce the same results on performing a further series of experiments.

The Editor has agreed to the authors' request, and therefore this article has been retracted from Oncology Letters. All the authors agree to this retraction. The authors apologize to the readership of the Journal for any inconvenience caused.

Related Articles

Journal Cover

December-2020
Volume 20 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sun X, Xu W, Zang C and Li N: [Retracted] miRNA‑520c‑3p accelerates progression of nasopharyngeal carcinoma via targeting RAB22A. Oncol Lett 20: 319, 2020.
APA
Sun, X., Xu, W., Zang, C., & Li, N. (2020). [Retracted] miRNA‑520c‑3p accelerates progression of nasopharyngeal carcinoma via targeting RAB22A. Oncology Letters, 20, 319. https://doi.org/10.3892/ol.2020.12182
MLA
Sun, X., Xu, W., Zang, C., Li, N."[Retracted] miRNA‑520c‑3p accelerates progression of nasopharyngeal carcinoma via targeting RAB22A". Oncology Letters 20.6 (2020): 319.
Chicago
Sun, X., Xu, W., Zang, C., Li, N."[Retracted] miRNA‑520c‑3p accelerates progression of nasopharyngeal carcinoma via targeting RAB22A". Oncology Letters 20, no. 6 (2020): 319. https://doi.org/10.3892/ol.2020.12182